



Contents lists available at ScienceDirect

Pharmacology & Therapeutics

journal homepage: www.elsevier.com/locate/pharmthera

Review article

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies

Yu Chen^{a,b,c,*}, Amy K.Y. Fu^{a,c}, Nancy Y. Ip^{a,c,**}^a Division of Life Science, State Key Laboratory of Molecular Neuroscience and Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China^b The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China^c Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST Shenzhen Research Institute, Shenzhen, Guangdong, China

ARTICLE INFO

Keywords:

Synaptic failure
Excitotoxicity
Beta-amyloid
Tau
Receptor
Kinase

ABSTRACT

Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the elderly population, is characterized by progressive cognitive decline and pathological hallmarks of amyloid plaques and neurofibrillary tangles. However, its pathophysiological mechanisms are poorly understood, and diagnostic tools and interventions are limited. Here, we review recent research on the amyloid hypothesis and beta-amyloid-induced dysfunction of neuronal synapses through distinct cell surface receptors. We also review how tau protein leads to synaptotoxicity through pathological modification, localization, and propagation. Finally, we discuss experimental therapeutics for AD and propose potential applications of disease-modifying strategies targeting synaptic failure for improved treatment of AD.

© 2018 Elsevier Inc. All rights reserved.

Contents

1. Introduction	0
2. Synapses and cognitive functions	0
3. A β -mediated neurotoxicity and synaptic dysfunction	0
4. Tau pathology and synaptic dysfunction in Alzheimer's disease	0
5. Current experimental therapeutics for Alzheimer's disease	0
6. Synapse-modifying strategies for Alzheimer's disease therapeutics	0
7. Concluding remarks	0
Conflict of interest statement	0
Acknowledgments	0
References	0

Abbreviations: A β , beta-amyloid; AD, Alzheimer's disease; AMPA, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APP, amyloid precursor protein; Cdk5, cyclin-dependent kinase 5; GPCRs, G protein-coupled receptors; GSK-3 β , glycogen synthase kinase 3 beta; HMW, high-molecular-weight; LMW, low-molecular-weight; LTD, long-term depression; LTP, long-term potentiation; MC4R, melanocortin 4 receptor; mGluRs, metabotropic glutamate receptors; NMDA, N-methyl-D-aspartic acid; PKA, protein kinase A; PrP^C, cellular prion protein.

* Correspondence to: Y. Chen, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.

** Correspondence to: N. Y. Ip, Division of Life Science, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China.

E-mail addresses: yu.chen@siat.ac.cn (Y. Chen), boip@ust.hk (N.Y. Ip).

1. Introduction

Alzheimer's disease (AD), which was first described in 1906 by Dr. Alois Alzheimer, has become the most prevalent and burdensome neurodegenerative disease (Querfurth & LaFerla, 2010). Current treatments merely ameliorate symptoms and are unable to stop or reverse disease progression. Despite intensive research efforts towards AD over several decades, researchers have not successfully translated promising disease-modifying strategies identified in laboratories into clinical applications.

The etiology of AD is extremely complex and involves the combinatorial contributions of multiple intrinsic and extrinsic factors. The

hallmarks of AD are the extracellular deposition of senile plaques formed by beta-amyloid ($A\beta$) and the intracellular accumulation of neurofibrillary tangles formed by hyperphosphorylated tau protein. However, the mechanistic linkage between these hallmarks and the cognitive deficits observed in AD remain poorly understood. Accumulating evidence suggests that the loss of neuronal synapses occurs in the early stage of AD pathogenesis and is associated with cognitive decline (Querfurth & LaFerla, 2010). Furthermore, recent research suggests that $A\beta$ and tau act at neuronal synapses and exert their pathological roles during disease progression (Forner, Baglietto-Vargas, Martini, Trujillo-Estrada, & LaFerla, 2017). Accordingly, in this review, we focus on the molecular mechanisms underlying the dysfunction of excitatory synapses in AD and discuss potential disease-modifying strategies.

2. Synapses and cognitive functions

Synapses are formed when navigating axons identify their correct target cells. This is followed by the specialization of presynaptic axon terminals, which release vesicles containing neurotransmitters, and the maturation of postsynaptic compartments, which transduce the incoming signals by neurotransmitter receptors such as *N*-methyl-D-aspartic acid receptors (NMDA receptors) and α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA receptors) (Waites, Craig, & Garner, 2005). The number, structure, and function of synapses change over time, strengthening or weakening their synaptic contacts. This process, termed "synaptic plasticity," optimizes the neuronal connections crucial for cognitive functions such as learning and memory. Synapses are the basic unit that transduces information among neurons and are under tight spatiotemporal regulation. Importantly, their aberrant function might be implicated in various neurological disorders (Fu & Ip, 2017). Specifically, synaptic dysfunction is most closely correlated with cognitive decline in AD patients. Upon postmortem examination, the brains of AD patients have significantly fewer synapses than those of healthy controls (de Wilde, Overk, Sijben, & Masliah, 2016). Synaptic loss or deregulation is also apparent in various AD transgenic animal models, accompanied by deficits in learning and memory (Forner et al., 2017; Sheng, Sabatini, & Sudhof, 2012). Restoring excitatory synaptic transmission in the hippocampus through different approaches including genetic manipulation or administration of small molecules, short peptides, or antibodies can effectively ameliorate the cognitive deficits in AD animal models (Nistico, Pignatelli, Piccinin, Mercuri, & Collingridge, 2012), thus opening new avenues for developing disease-modifying approaches to treat AD progression.

3. $A\beta$ -mediated neurotoxicity and synaptic dysfunction

3.1. Amyloid hypothesis

$A\beta$ peptides are short peptides comprising 39–43 amino acids that are generated from amyloid precursor protein (APP). APP is a ubiquitously expressed type I integral membrane glycoprotein (Sosa et al., 2017) that can undergo two competitive cleavage pathways: the amyloidogenic or non-amyloidogenic pathway. In the amyloidogenic pathway, APP is sequentially cleaved by β -secretase and γ -secretase, generating a soluble extracellular fragment (sAPP β), $A\beta$, and an APP intracellular domain (AICD). Meanwhile, in the non-amyloidogenic pathway, α -secretase processes APP at the $A\beta$ domain to generate sAPP α , followed by γ -secretase cleavage, which generates P3 peptide and AICD fragment (Sheng et al., 2012). $A\beta_{42}$ is the most toxic $A\beta$ species generated by amyloidogenic processing. "The amyloid hypothesis," which posits that $A\beta$ plays a causative role in AD pathogenesis was supported by early genetics studies showing that autosomal-dominant mutations or duplication of APP, or mutations of PSEN1 or PSEN2 (the genes that encode γ -secretase subunits) lead to early-onset familial AD (Hardy & Selkoe, 2002). The senile plaques formed by extracellular $A\beta$

deposition were thought to be the major pathogenic substance in AD. However, clinical investigations of AD patients did not reveal a strong association between extracellular $A\beta$ deposition (i.e., amyloid plaque) burden and the level of cognitive decline (Querfurth & LaFerla, 2010).

Nonetheless, the roles of $A\beta$ in synaptic dysfunction and cognitive decline were re-examined following the identification of soluble $A\beta$ oligomers, also known as $A\beta$ -derived diffusible ligands, which are the major form of $A\beta$ aggregates that induce synaptotoxicity (Sheng et al., 2012). $A\beta$ monomers go through distinct pathways to generate higher-order assemblies (Velasco et al., 2012), indicating the concurrence of a mixture of $A\beta$ species including low-molecular-weight (LMW) oligomers (e.g., dimers, trimers, and tetramers) and high-molecular-weight (HMW) oligomers (50–150 kDa) (Forner et al., 2017). During disease progression, the conformations of $A\beta$ and APP take on pathological phenotypes and $A\beta$ aggregation begins to be enriched at synapses, which occurs before the formation of amyloid plaques or accumulation of phosphorylated tau at synapses (Bilousova et al., 2016; Klementieva et al., 2017). Furthermore, *in vitro* administration of $A\beta$ to neurons or organotypic brain slices reduces the number of dendritic spines, increases synaptic protein loss, and compromises the surface expression of neurotransmitter receptors; this occurs together with a reduction of miniature excitatory postsynaptic currents or impairment of synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD). Similar findings have also been reported in various AD transgenic mouse models with increased levels of soluble $A\beta$ species (Tu, Okamoto, Lipton, & Xu, 2014). Nonetheless, oligomeric $A\beta$ might exert its action in a hypothetical, inverted, U-shaped profile (Palop & Mucke, 2010). That is, intermediate levels of $A\beta$ (i.e., much lower than the pathological level of $A\beta$ in AD) might potentiate presynaptic facilitation and enhance cognitive performance in mice (Abramov et al., 2009; Puzzo et al., 2008). However, abnormally low levels of $A\beta$ can result in compromised presynaptic facilitation leading to impaired synaptic plasticity, whereas pathologically high levels of $A\beta$ are the key factor in the induction of synaptotoxicity in AD (Palop & Mucke, 2010). Accordingly, research on the molecular mechanisms underlying $A\beta$ -induced synaptic toxicity has provided invaluable information and targets for AD intervention.

The heterogeneity of $A\beta$ species coexisting in the AD brain obfuscates their actions at synapses, as synapses can be contacted by a mixture of $A\beta$ species that might induce diverse biological reactions. High-throughput imaging analysis shows that $A\beta$ oligomers of varying size are present in the synaptic regions (Pickett et al., 2016). Compared to LMW aggregates, HMW $A\beta$ oligomers exhibit higher binding affinity to synapses in mature hippocampal neurons; indeed, strong synaptic binding is only observed in a subset of HMW oligomers (Velasco et al., 2012). Although HMW oligomers are dominant in the aqueous extracts of human AD brains, they are less active and toxic to neurons. HMW $A\beta$ oligomers cause a transient decline of cognitive functions without obvious synaptic pathology, whereas LMW $A\beta$ oligomers induce more rapid and persistent cognitive impairment with significant reduction of pre- and postsynaptic proteins (Figueiredo et al., 2013). However, these HMW oligomers can dissociate into the more active LMW populations to impair synaptic plasticity, and the amyloid plaques likely play a role in sequestering HMW oligomers to control the generation of LMW oligomers (T. Yang, Li, Xu, Walsh, & Selkoe, 2017). In contrast, the dissociation of $A\beta$ oligomers into monomers by an $A\beta$ -binding small molecule reduces the synaptotoxicity and $A\beta$ pathology *in vivo* (Kim et al., 2015). Therefore, it is important to identify the distinct synaptic targeting mechanisms of LMW and HMW $A\beta$ oligomers in order to understand the synaptotoxicity of $A\beta$ and design $A\beta$ -based therapeutic strategies.

3.2. $A\beta$ -induced presynaptic dysfunction

Under pathological conditions, $A\beta$ predominantly accumulates at synapses upon aberrant accumulation of β -site APP cleaving enzyme 1

(BACE1), the major neuronal β -secretase for A β generation, at the presynaptic terminals (Ye et al., 2017). The elevated synaptic A β level subsequently leads to deficits in crucial presynaptic functions including axonal transport, synaptic vesicle cycling, and neurotransmitter release.

Axonal transport is a key process that transfers cellular components to and from the cell soma. A β oligomers co-localize with axonal voltage-gated calcium channels to facilitate calcium influx and impair fast axonal transport of cargos such as brain-derived neurotrophic factor (BDNF) (Gan & Silverman, 2015). A β can disrupt axonal transport via mechanisms independent of tau or microtubule destabilization but requires the activation of NMDA receptors, calcineurin (a calcium-dependent phosphatase), glycogen synthase kinase 3 beta (GSK-3 β), or casein kinase 2 (CK2) (Decker, Lo, Unger, Ferreira, & Silverman, 2010; Gan & Silverman, 2015; Pigino et al., 2009; Ramser et al., 2013). Recent studies have revealed that A β oligomers that bind to distal axons sequentially trigger local protein synthesis of transcription factor ATF4 within the axon and retrograde axonal transport to the soma, leading to neuronal degeneration (Baleriola et al., 2014). These findings suggest that presynaptic A β induces prominent neurodegeneration not only by disrupting physiological axonal transport, but also by initiating pathological axonal transport to spread AD pathology in a retrograde manner.

Neurotransmitter-containing synaptic vesicles are the key messengers that relay trans-synaptic signals. A β affects the key steps of synaptic vesicle cycling, including the trafficking, release, and recycling of synaptic vesicles (Ovsepian, O'Leary, Zaborszky, Ntziachristos, & Dolly, 2018). Oligomeric A β -induced presynaptic calcium influx can enhance the release probability of neurotransmitter-containing synaptic vesicles, resulting in an abnormally high level of glutamate in the extracellular space and enhanced spontaneous postsynaptic activity (Brito-Moreira et al., 2011). APP dimers at the presynaptic plasma membrane can serve as A β receptors and mediate the presynaptic potentiation via Go-coupled intracellular signaling; in turn, this further enhances A β generation, thus constituting a positive feedback mechanism of A β -induced synaptic hyperactivity (Fogel et al., 2014). In addition to potentiating the release probability of the readily releasable pool of synaptic vesicles, A β impairs vesicle recycling by reducing the recycling pool and increasing the resting pool via the calpain-dependent increase of the activity of cyclin-dependent kinase 5 (Cdk5). Indeed, Cdk5 inhibitor exhibits a beneficial effect on the recovery of the size of the vesicle pool, providing a brake for the A β -induced deregulation of synaptic vesicle cycling (Park, Jang, & Chang, 2013).

D-Serine is the dominant co-agonist of NMDA receptor-mediated synaptotoxicity. D-Serine level is elevated in multiple brain regions in AD patients, including the hippocampus, cortex, and cerebrospinal fluid (CSF), although the increase of D-serine in CSF is controversial (Biemans et al., 2016; Madeira et al., 2015). Upon binding to neurons, A β triggers the increase of extracellular D-serine, probably through alanine-serine-cysteine transporter 1 (asc-1) at the presynaptic terminal (Ferreira & Klein, 2011; Martineau, Parpura, & Mothet, 2014). Interestingly, loss of APP leads to a reduction of extracellular D-serine, concomitant with an increase of total D-serine and a decrease of dendritic spine dynamics (Zou et al., 2016). Therefore, blocking the pathological APP cleavage that overproduces A β and promotes the physiological functions of APP is crucial for maintaining D-serine homeostasis and cognitive functions. It should be noted that glial cells reserve a large pool of D-serine, which might come from the uptake of released neuronal D-serine synthesized from glial-derived L-serine (Martineau et al., 2014). However, the major source of aberrant D-serine release upon AD pathogenesis and the underlying signaling mechanisms remain unclear.

3.3. A β -induced postsynaptic dysfunction

A β oligomers target the postsynaptic compartment of excitatory synapses with high affinity, altering the structure, composition, and function of synapses (Koffie et al., 2009). The action of A β oligomers at

postsynaptic membranes can be mediated through their binding to various cell surface molecules, forming putative A β receptor complexes to potentiate synaptotoxicity. However, it is unclear which molecules or mechanisms underlie the initial targeting and binding of A β to synapses. Furthermore, the specificity of A β species (i.e., LMW vs. HMW) targeting different "receptors" or cell-type selectivity is also unclear. Because of space limitations, this review will focus on ionotropic neurotransmitter receptors, G protein-coupled receptors (GPCRs), and receptor tyrosine kinases. Other A β receptors or receptor complexes on neuron membranes, such as cellular prion protein (PrP^C), Frizzled receptors, Neuroigin, insulin receptor, paired immunoglobulin-like receptor B (PirB), and Fc γ receptor II-b (Fc γ RIIb) have been reviewed elsewhere (Ferreira, Lourenco, Oliveira, & De Felice, 2015; Xia, Cheng, Yi, Gao, & Xiong, 2016).

3.3.1. NMDA receptors and AMPA receptors

NMDA receptors and AMPA receptors are two key types of ionotropic glutamate receptors at excitatory postsynaptic membranes (Scheefhals & MacGillavry, 2018). NMDA receptor is a heterotetramer comprising two GluN1 and two GluN2 subunits and is enriched at the postsynaptic membranes of excitatory neurons. The activation of its channel activity is controlled by glutamate binding, D-serine or glycine binding, and membrane depolarization to release Mg²⁺ block. Upon activation, NMDA receptor facilitates calcium influx to stimulate intracellular signaling cascades such as calcium/calmodulin-dependent protein kinase II (CaMKII) or calcineurin-mediated calcium signaling in postsynaptic neurons (Scheefhals & MacGillavry, 2018). A β oligomers bind to NMDA receptor-containing protein complexes at the neuronal surface and elicit distinct downstream pathways to induce synaptotoxic effects (De Felice et al., 2007; Decker et al., 2010). For example, NMDA receptor-dependent LTD is facilitated by A β via the inhibition of glutamate uptake and increased extracellular glutamate level (S. Li et al., 2009). Upon A β treatment, NMDA receptors recruit PTEN (a lipid phosphatase) to the postsynaptic density and facilitate synaptic depression (Knafo et al., 2016). Interestingly, A β -induced synaptotoxicity is dependent on the subunit composition of NMDA receptors. For example, GluN2A but not GluN2B is required for the A β -induced loss of dendritic spines (Tackenberg et al., 2013). In contrast, A β activates GluN2B-containing NMDA receptors at extrasynaptic regions through α 7 nAChR-mediated astrocytic glutamate release, which leads to the aberrant activation of p38 mitogen-activated kinase (MAPK), inhibition of cAMP response element-binding (CREB) signaling, and impairment of LTP (Li et al., 2011; Talantova et al., 2013). The activation of extrasynaptic NMDA receptors also leads to the impairment of synaptic plasticity and cognitive functions by facilitating the proteasome-dependent degradation of the DNA repair factor, BRCA1 (Suberbielle et al., 2015).

On the other hand, AMPA receptors are the key glutamate receptors that mediate fast excitatory synaptic transmission. They have a heterotetrameric subunit composition, with dimerized dimers of GluA1, GluA2, GluA3, or GluA4 subunits (Greger, Ziff, & Penn, 2007). Early studies showed that AD patients exhibit reduced AMPA receptor expression in the entorhinal cortex and hippocampus (Dewar, Chalmers, Graham, & McCulloch, 1991; Yasuda et al., 1995). Furthermore, elevated A β level can induce the removal of AMPA receptors from excitatory synapses, which in turn leads to a loss of dendritic spines and synaptic depression (Chang et al., 2006; Guntupalli, Widagdo, & Anggono, 2016; Hsieh et al., 2006; Minano-Molina et al., 2011). While the functions of AMPA receptors can be modulated by post-translational modification (e.g., phosphorylation and ubiquitination) of its subunits (Chater & Goda, 2014), A β reduces GluA1 phosphorylation at Ser845 with a concomitant increase of GluA1 ubiquitination. Given that GluA1 phosphorylation at Ser845 is critical for AMPA receptor trafficking, expression of phosphomimetic GluA1 mutant reduces AMPA receptor ubiquitination and perturbs the A β -induced removal of AMPA receptors from the synaptic surface,

suggesting that GluA1 phosphorylation at Ser845 is negatively associated with ubiquitination in AD (Guntupalli et al., 2017). In addition, an elevated Ca^{2+} level in the presence of A β triggers the protein kinase C (PKC)-dependent phosphorylation of GluA2 at Ser880 and its subsequent removal from synapses (Liu, Gasperini, Foa, & Small, 2010). However, a recent study demonstrated that only GluA3-expressing neurons suffer from A β -induced insult, although the underlying mechanism remains elusive (Reinders et al., 2016). Furthermore, the precise composition of AMPA receptors that mediates A β -induced synaptic dysfunction awaits further investigation.

3.3.2. GPCRs: Metabotropic glutamate receptors and melanocortin 4 receptor

Metabotropic glutamate receptors (mGluRs) belong to the GPCR superfamily, which couple different G proteins to elicit downstream signaling through phospholipase C or adenylate cyclase and modulate glutamatergic synaptic transmission (Reiner & Levitz, 2018). A member of group I mGluRs, mGluR5, plays a modulatory role in regulating excitatory transmission at glutamatergic synapses and regulating NMDA receptor-dependent synaptic plasticity (Harney, Rowan, & Anwyl, 2006). Recent evidence further suggests that mGluR5 is a key player in A β -induced synaptotoxicity and a potential therapeutic target for AD (Kumar, Dhull, & Mishra, 2015). After A β oligomers bind to and accumulate at synaptic sites, the lateral diffusion of the oligomers decreases sharply and is accompanied by aberrant clustering of mGluR5, which results in synaptotoxicity (Renner et al., 2010). Moreover, in an AD transgenic mouse model that overproduces A β , genetic depletion of mGluR5 alleviates spatial learning deficits and amyloid pathology while reducing the activity of mammalian target of rapamycin (mTOR) and the expression of downstream fragile-X mental retardation protein (FMRP); in turn, this downregulates the translation and processing of APP (Hamilton, Esseltine, DeVries, Cregan, & Ferguson, 2014). Interestingly, mGluR5 physically interacts with PrP^c, a key component of putative A β receptor complex, coupling A β oligomers to the activation of Fyn kinase and neurotoxicity (Haas et al., 2016; Um et al., 2012; Um et al., 2013). The interaction between mGluR5 and PrP^c increases upon A β binding, inducing the deregulation of protein translation in dendrites through the phosphorylation of eukaryotic elongation factor 2 (eEF2), accompanied by a loss of dendritic spines and the facilitation of LTD (Haas, Kostylev, & Strittmatter, 2014; N. W. Hu et al., 2014; Um et al., 2013). Administration of mGluR5 agonist upregulates the association between mGluR5 and PrP^c, whereas administration of its antagonist downregulates this interaction (Haas et al., 2014). Thus, attenuating mGluR5 activation is an alternative approach to ameliorate A β -induced synaptic failure.

Meanwhile, melanocortin 4 receptor (MC4R) and its ligand, α -melanocyte-stimulating hormone (α -MSH), are well known for their roles in metabolic homeostasis (Krushes, Lowell, & Garfield, 2016). Our laboratory previously identified a microcircuit in the hippocampus: pro-opiomelanocortin (POMC) neurons expressed in the CA3 region generate α -MSH via proteolytic cleavage, which activates MC4R expressed in the CA1 region (Shen et al., 2016). Furthermore, postsynaptic activation of MC4R promotes the maturation of dendritic spines and augments the protein kinase A (PKA)-dependent phosphorylation of AMPA receptor subunit GluA1 at Ser845 to enhance both its surface expression at synapses and LTP (Shen, Fu, Cheng, Fu, & Ip, 2013). Further studies revealed that MC4R activation is deregulated in AD mouse models during disease progression (Shen et al., 2016). Importantly, attenuating MC4R activation by either presynaptic depletion of POMC neurons or postsynaptic antagonization of MC4R with its endogenous inverse agonist, agouti-related protein (AgRP), further impairs LTP in AD model mice (i.e., APP/PS1 mice). Meanwhile, the LTP deficits can be rescued by enhancing MC4R activity through the MC4R agonist, D-Tyr MTII (Shen et al., 2016). Thus, the findings of these studies provide a novel approach to targeting a specific microcircuit within the hippocampus to restore cognitive function in AD.

3.3.3. Receptor tyrosine kinases: EphA4 and EphB2

Eph receptors are by far the largest family of receptor tyrosine kinases. The 16 identified members can be divided into the EphA and EphB families, which preferentially bind to ephrinA and ephrinB ligands, respectively. The membrane-tethered nature of these receptors and ligands enables bidirectional signal transduction in both receptor- and ligand-expressing cells (Chen, Fu, & Ip, 2012; Kania & Klein, 2016). We and others have demonstrated that activation of EphA4 signaling via neuron–glia communication induces the retraction of dendritic spines in hippocampal neurons and that chronic elevation of neuronal activity facilitates the removal of AMPA receptor subunit GluA1 via a ubiquitin-proteasome pathway mediated by EphA4 (Bourgin, Murai, Richter, & Pasquale, 2007; Filosa et al., 2009; Fu et al., 2007; Fu et al., 2011; Murai, Nguyen, Irie, Yamaguchi, & Pasquale, 2003; Zhou et al., 2007). On the other hand, EphB receptors (EphB1–EphB3) play important roles in the development and maturation of dendritic spines (Henkemeyer, Itkis, Ngo, Hickmott, & Ethell, 2003; Kayser, Nolt, & Dalva, 2008; Murata & Constantine-Paton, 2013). EphA4 and EphB2 expression is reduced in the brains of early AD patients (Braak stage II/III), and altered EphA4 localization in the hippocampus with a notable concentration in neuritic plaque areas can be detected as early as Braak stage II (Rosenberger et al., 2014; Simon et al., 2009). These findings suggest that Eph family receptors are involved in AD pathogenesis.

Soluble A β exhibits high affinity for the extracellular domain of EphB2, which leads to the proteasome-mediated degradation of EphB2. Restoring EphB2 expression in the hippocampus in AD transgenic model mice reverses their cognitive impairment (Cisse et al., 2011; Hu et al., 2017). The beneficial effect of EphB2 depends on its ability to transduce signaling via its intracellular domain. Meanwhile, the γ -secretase-dependent cleavage of EphB2, which generates a C-terminal fragment, is important for NMDA receptor phosphorylation and surface expression; this can be inhibited by AD-associated familial presenilin 1 mutant (Litterst et al., 2007; Xu, Litterst, Georgakopoulos, Zaganas, & Robakis, 2009). The C-terminal PDZ-binding motif of EphB2 is the critical motif for ameliorating A β -induced deficits through regulating the association between EphB2 and intracellular PDZ proteins (Miyamoto, Kim, Knox, Johnson, & Mucke, 2016). EphB2 activation might also suppress GSK-3 β activity and in turn alleviate tau hyperphosphorylation in AD (Jiang et al., 2015). Nevertheless, it remains unclear whether EphB1 and EphB3, which have overlapping functions with EphB2 at synapses (Henkemeyer et al., 2003), are also involved in A β -induced synaptic deficits and cognitive decline.

EphA4 is a substrate of γ -secretase, which cleaves EphA4 to generate EphA4 intracellular domain (EICD) upon elevated synaptic activity (Inoue et al., 2009). In the human AD brain, EICD level is reduced in the frontal lobes accompanied by reduced expression of its downstream effector, Rac1, which might be associated with the reduced dendritic spines and synaptic scaffold proteins observed in AD (Inoue et al., 2009; Matsui et al., 2012). EphA4 phosphorylation and activation are elevated in young AD model mice—much earlier than the appearance of obvious cognitive decline (Fu et al., 2014). Furthermore, the level of active EphA4 is significantly elevated in the human AD brain (Huang et al., 2017). Knockdown of EphA4 by shRNA or blockade of EphA4 activation by EphA4 inhibitory peptide, which targets its ligand-binding region, rescues the deficits of hippocampal LTP through the inhibition of the aberrant activation of downstream Cdk5 and c-Abl kinase (Fu et al., 2014; Vargas et al., 2014). The AD genetic risk factor, sortilin-related receptor with LDLR class A repeats (SORLA) might cause the deregulation of EphA4 in AD. Specifically, the activation and clustering of EphA4 are attenuated upon the interaction with SORLA. Moreover, enhancing SORLA–EphA4 interaction in SORLA transgenic mice ameliorates A β -induced synaptic deficits, neurodegeneration, and cognitive impairment (Huang et al., 2017). Nevertheless, further studies are needed to confirm whether blocking EphA4 activation and clustering in

postsynaptic neurons regulates astrocyte function through reverse signaling and in turn modulates synaptic functions in AD.

4. Tau pathology and synaptic dysfunction in Alzheimer's disease

4.1. Post-translational modification of tau

Tau is a major microtubule-associated protein that binds and stabilizes microtubules in neurons. Tau can undergo several post-translational modifications including phosphorylation, acetylation, glycosylation, glycation, nitration, sumoylation, ubiquitination, etc. Aberrant post-translational modifications, in particular, phosphorylation, induce conformational changes and aggregation of tau; this results in the formation of neurofibrillary tangles, one of the key hallmarks of neurodegeneration (Morris, Maeda, Vossel, & Mucke, 2011).

Phosphorylation is the most important post-translational modification of tau and can occur at serine/threonine sites, tyrosine sites, or both. Furthermore, the status of tau phosphorylation is an indicator of aberrant kinase and phosphatase activity during AD progression (Hanger, Anderton, & Noble, 2009). Accumulating evidence suggests that increased tau phosphorylation in CSF is a potential biomarker of AD that might help differentiate AD from other types of dementia (Blennow, Hampel, Weiner, & Zetterberg, 2010; Kandimalla et al., 2013).

Multiple sites of tau protein can be phosphorylated by proline-directed protein kinases (PDPKs) or non-proline-directed protein kinases (non-PDPKs) (Wang & Mandelkow, 2016). Key PDPKs that act on tau protein include Cdk5, GSK-3, and extracellular signal-related protein kinase (Erk). Aberrant Cdk5 activity in AD induces the loss of dendritic spines and impairment of synaptic plasticity as well as tau hyperphosphorylation (Kimura, Ishiguro, & Hisanaga, 2014). GSK-3 is believed to be the major kinase associated with the aberrant phosphorylation of tau. Interestingly, before GSK-3 acts on its target sites, it requires pre-phosphorylation of its substrate by priming kinases at the adjacent sites. Non-PDPKs such as PKA, CK1, and CK2 often play a regulatory or priming role in GSK-3-mediated phosphorylation. Cdk5 might also act as a priming kinase for GSK-3 (Hanger & Noble, 2011). These lines of evidence provide additional potential targets for antagonizing aberrant GSK-3 kinase activity in AD.

Recent evidence suggests that tau is acetylated in the brains of early-stage AD patients. Acetylation at multiple sites leads to decreased tau turnover, increased tau aggregation and phosphorylation, and increased cognitive impairment (Gorsky et al., 2017; Gorsky, Burnouf, Dols, Mandelkow, & Partridge, 2016; Min et al., 2015; Trzeciakiewicz et al., 2017). Acetylated tau protein exhibits increased somatodendritic localization and disrupts the postsynaptic localization of the memory-associated protein Kidney/BRAIn (KIBRA), activity-dependent cytoskeletal dynamics, and AMPA receptor trafficking, consequently impairing synaptic plasticity and memory functions (Sohn et al., 2016; Tracy et al., 2016). Furthermore, investigation of the enhanced nitric oxide signaling through glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in AD brains revealed that nitric oxide shifts the balance between acetyltransferase p300 and deacetylase sirtuin towards tau acetylation; moreover, attenuating GAPDH-mediated nitric oxide signaling rescues the A β -induced memory impairment (Sen, Saha, & Sen, 2018). However, further study is needed to understand the biological relevance of different post-translational modifications of tau as well as the factors that initiate the changes in pathological conditions.

4.2. Pathological tau disrupts synaptic functions

Pathological modifications of tau alter its binding affinity for distinct partners, accompanied by aberrant aggregation, missorting to subcellular compartments, and enhanced propagation to different brain regions, which result in widespread tauopathy in AD (Spillantini & Goedert, 2013).

4.2.1. Tau-induced dysfunction of axonal transport and synaptic transmission

Tau is a microtubule-associated protein predominantly enriched in axons under physiological conditions. Interestingly, the physiological binding of tau to microtubules competes with its pathological misfolding, because the two processes require the same set of evolutionarily conserved residues (Kadavath et al., 2015). Moreover, tau competes with dyneins and kinesins (retrograde and anterograde molecular motors, respectively) through binding to microtubules, limiting the speed of axonal transport in both directions (Dixit, Ross, Goldman, & Holzbaur, 2008). In a recent study, disease-associated tau mutants exhibited a decreased association rate with microtubules with an unchanged dissociation rate, resulting in a net decrease of microtubule binding (Niewidok et al., 2016). In AD, the pathological hyperphosphorylation of tau leads to its detachment from microtubules, which is accompanied by decreased cytoskeletal stability and impaired axonal transport. The phosphatase-activating domain at the N-terminus of tau, which is present in pathological aggregates but not in soluble monomers, stimulates the activity of protein phosphatase 1 (PP1), which in turn dephosphorylates and activates GSK-3 β to phosphorylate kinesin light chain; this causes cargo detachment and consequently disrupts anterograde transport (Kanaan et al., 2011; Kanaan et al., 2012; Stern, Lessard, Hoeprich, Morfini, & Berger, 2017). In addition, the extracellularly localized oligomeric forms of tau can be taken up by neurons, trigger abnormal tau accumulation in axons, and deregulate the axonal transport of membranous organelles (Swanson et al., 2017; Wu et al., 2013). On the other hand, pathological tau, with its N-terminal sequence, binds to synaptic vesicles through synaptogyrin-3 (a transmembrane vesicle protein) and disrupts presynaptic functions (McInnes et al., 2018; Zhou et al., 2017). Presynaptic accumulation of tau induces a transient increase of spontaneous neurotransmitter release mediated by intracellular calcium release from the endoplasmic reticulum; this is followed by persistent synaptic depression due to the resultant deficits in exocytosis (Moreno et al., 2011; Moreno et al., 2016). In addition, the presence of a pro-aggregation tau mutant at presynaptic boutons leads to the enlargement of boutons and depletion of the synaptic vesicle pool, concomitant with impaired synaptic transmission and plasticity (Decker et al., 2015; Fa et al., 2016). Thus, the maintenance of microtubule stability, transport along axons, and synaptic vesicle cycling require an optimal level of presynaptic tau.

4.2.2. Missorting of pathological tau

A tau diffusion barrier at the axon initial segment controls the homeostatic balance of axonal and somatodendritic tau (Li et al., 2011). The physiological translocation of tau to synapses is dependent on neuronal activity, which is disrupted in the presence of oligomeric A β (Frandemichie et al., 2014). The A β -induced inhibition of microtubule dynamics in the axon initial segment might also impair the normal sorting of tau (Tsushima et al., 2015; Zempel et al., 2017). Consistent with this finding, a substantial portion of tau protein in AD patients is translocated to the postsynaptic compartments, shifting the balance between axonal and somatodendritic localization (Tai et al., 2014). Tau proteins invading neuronal dendrites destabilize microtubules by recruiting spastin, a microtubule-severing enzyme (Zempel et al., 2013). More importantly, the infiltration of tau into dendritic spines results in reduced synaptic clustering of both NMDA and AMPA receptors, compromised excitatory synaptic transmission, and memory deficits (Hoover et al., 2010; Kim et al., 2016; Xia, Li, & Gotz, 2015; Yin et al., 2016; Zhao et al., 2016). Missorting of truncated tau with lower Fyn-binding affinity to cell soma or knockout of tau disrupts Fyn enrichment at the postsynaptic density as well as the subsequent phosphorylation of NMDA receptor subunit GluN2B and recruitment of PSD-95, consequently alleviating A β -induced excitotoxicity (Ittner et al., 2010; Robertson et al., 2011). In addition, abolishing the specific phosphorylation of tau at KxGS motifs by kinases such as AMP-activated kinase (AMPK) counteracts the A β -induced loss of dendritic spines and

restores synaptic functions (Mairet-Coello et al., 2013; Zempel et al., 2013). However, postsynaptic p38 γ -mediated tau phosphorylation mitigates A β -induced excitotoxicity, suggesting the existence of protective tau phosphorylation in the postsynaptic compartment (Ittner et al., 2016). Therefore, targeting the somatodendritic missorting of tau and its specific phosphorylation at the postsynaptic compartment are alternative approaches for ameliorating synaptotoxicity in AD.

4.2.3. Tau propagation in AD

AD Braak staging is a tauopathy-based method for describing the gradual progression of neurofibrillary tangles from the transentorhinal region, to the limbic regions such as the hippocampus, and finally to the extensive neocortical regions (Braak & Braak, 1995). Seed-competent tau in the synaptic fraction is enriched before obvious tau pathology manifests in the human brain (DeVos et al., 2018). A low-abundance HMW tau species has been identified as an endogenously propagated form of tau (Takeda et al., 2015). The spread of tau aggregation from one brain region to another is not dependent on the proximity of two regions, but rather occurs between interconnected regions, suggesting that a trans-synaptic propagation mechanism is responsible (Goedert, Eisenberg, & Crowther, 2017). For example, tau has been observed spreading in a circuit-based manner from the entorhinal cortex to the dentate gyrus and cornu ammonis regions in the hippocampus (C. Li & Götz, 2017). Furthermore, the presence of synaptic contacts and elevated neuronal activity can enhance the spread of tau (Calafate et al., 2015; de Calignon et al., 2012; Wu et al., 2016). The identification of microglia-mediated tau internalization and seeding via exosomes indicates the existence of an alternative tau propagation mechanism independent of synaptic connections (Asai et al., 2015). Tau is also suggested to propagate in a prion-like manner (Clavaguera et al., 2013; Kaufman et al., 2016; Sanders et al., 2014). However, the finding that the propagation of misfolded tau does not require endogenous tau is unconvincing with the prion-like propagation model, which posits that the templated misfolding of endogenous tau in recipient cells is necessary to maintain the prion-like tau conformation (Wegmann et al., 2015). Multiple approaches to block tau propagation, such as reduction of acetylation, inhibition of endocytosis, depletion of microglia, or administration of specific antibodies, can efficiently alleviate tau pathology, thereby opening new avenues to target tauopathy in AD (Asai et al., 2015; Calafate, Flavin, Verstreken, & Moechars, 2016; Min et al., 2018; Yanamandra et al., 2013). However, the specific tau species required for spreading, differential mechanisms for the release and uptake of tau of different molecular weights and conformations, and the cellular machinery that determines the circuit specificity of the spread of tau remain unclear.

5. Current experimental therapeutics for Alzheimer's disease

The currently available treatments for AD target cholinergic neurotransmission (i.e., donepezil, rivastigmine, and galantamine), glutamatergic synapses (i.e., memantine), or both (i.e., Namzaric, a combination of donepezil and memantine), providing limited relief of AD symptoms (Knight, Khondoker, Magill, Stewart, & Landau, 2018). While more than 100 clinical trials have failed, there are 112 ongoing trials of drugs with anti-amyloid, anti-tau, anti-inflammation, neurotransmitter-modulating, or other effects. Among these trials, amyloid- and tau-related strategies remain predominant (Cummings, Lee, Ritter, & Zhong, 2018).

5.1. Amyloid-related clinical development

Several anti-amyloid immunotherapies and small molecules have been designed to decrease the amyloid load in the brain either by reducing the generation and aggregation of A β or by enhancing its clearance.

Strategies to alleviate A β toxicity, such as immunotherapies sequestering specific A β species and chemicals blocking amyloid aggregation, have been extensively investigated. Six immunotherapies are currently

undergoing phase III development (Cummings et al., 2018). One such immunotherapy, aducanumab (NCT01677572), is a human IgG1 monoclonal antibody derived from a cognitively normal donor that preferentially binds to A β aggregates in the parenchymal tissue, and exhibits a dose- and time-dependent effect on the removal of amyloid from the patient's brain while slowing the rate of cognitive decline (Sevigny et al., 2016). In contrast, solanezumab (NCT01900665) is a humanized monoclonal IgG1 antibody that targets A β monomers and aims to reduce synaptotoxic A β species by enhancing the clearance of soluble A β . However, in a recent double-blind, placebo-controlled phase III trial, its effect on preventing cognitive decline in mild AD was not significant (Honig et al., 2018). Despite many ongoing clinical trials, no strategy has proven successful. In particular, the specific A β species that is toxic in the brain or at synapses and the precise action mechanisms of A β species with different oligomeric forms or conformations remain unclear. Further investigation into these questions would aid the development of A β -targeting therapies with higher efficacy and specificity.

Another key target in this category is β -secretase 1, also known as BACE1, which controls the rate-limiting step in the cleavage of APP at the β -site to generate A β (Das & Yan, 2017). In AD animal models, compromising BACE1 function by inhibiting its activity, reducing its expression, or introducing a protective mutant (A673T in APP) to the sequences near the β -site leads to the reduction of A β and alleviates memory impairment (Koelsch, 2017; Vassar, 2014). Among the 14 anti-amyloid therapies at the phase III stage, 5 are BACE1 inhibitors: verubecestat (NCT01953601), lanabecestat (NCT02245737, NCT02783573, NCT02972658), elenbecestat (NCT03036280, NCT02956486), JNJ-54861911 (NCT02569398), and CNP520 (NCT03131453) (Cummings et al., 2018). However, the side effects of inhibiting BACE1 must be considered. In addition to APP, BACE1 acts on other putative substrates in the nervous system (Vassar, 2014). Thus, BACE1 inhibition might abolish the processing of various physiological substrates that affect neuronal functions. On the other hand, attenuating BACE1 function shifts the balance towards the non-amyloidogenic pathway to generate more sAPP α and P3 peptide, which might also disturb neuronal function.

5.2. Tau-related clinical development

Most of the tau-related approaches at the phase II or III stage utilize disease-modifying strategies either by blocking tau aggregation or neutralizing/removing tau to hinder its transneuronal propagation. Other indirect approaches targeting intracellular pathology include stabilizing microtubules or manipulating tau kinases or phosphatases (Cummings et al., 2018).

The only anti-tau agent in the phase III stage is TRx0237 (NCT01689246), which is a reduced form of methylthioninium chloride designed to prevent or dissolve tau aggregation to alleviate tauopathy (Seripa et al., 2016). However, phase III trials of different doses of TRx0237 showed no beneficial effects on the cognitive performance of mild-to-moderate AD patients (Gauthier et al., 2016). Small molecules targeting the post-translational modification of tau, such as GSK-3 β -mediated or Fyn-mediated phosphorylation, are under development and aim to block abnormal tau phosphorylation during AD pathogenesis (C. Li & Götz, 2017).

On the other hand, several immunotherapies that extracellularly target tau propagation are in phase II trials. For example, ABBV-8E12 (NCT02880956) blocks tau seeding by recognizing the aggregated form of tau, while RO7105705 (NCT03289143) binds both monomeric and oligomeric tau species (Doody, 2017; West et al., 2017). Meanwhile, LY3303560 (NCT02754830, NCT03019536) is an agent entering phase II trials (Alam et al., 2017) that selectively binds to tau aggregates over monomers; however, it remains unclear if its primary effect is indeed due to neutralizing extracellularly propagating tau. The key benefits of this strategy are easy access to the targets and that antibody uptake by neurons is not required.

Similar to the development of A β -related interventions, researchers are still investigating the precise roles of different tau species. The extent to which the extracellular tau pool contributes to AD is also unclear. Therefore, developing tau-related agents that specifically target pathological epitopes might be a path for future exploration.

6. Synapse-modifying strategies for Alzheimer's disease therapeutics

Synaptic failure is an early sign of AD pathogenesis and is closely associated with the observed cognitive decline in AD. Oligomeric A β (Fig. 1) or misfolded tau (Fig. 2) interacts with cell surface receptors, scaffold proteins, or intracellular signaling molecules, consequently deteriorating synaptic structure and function. Therefore, targeting the synaptotoxic A β or tau species, or the deregulated synaptic components at the early stage of AD might stop or reverse the disease progression.

6.1. Approaches to alleviate A β load

Approaches to alleviate A β load by enhancing its clearance or sequestration, reducing generation, or shifting the balance between the amyloidogenic and non-amyloidogenic pathways have been studied extensively and reviewed recently (Sala Frigerio & De Strooper, 2016). However, no effective intervention based on this paradigm has been developed. From a synaptic perspective, although oligomeric A β plays a key role in the synaptotoxicity in AD, the precise A β species that target

specific types of synapses remain unknown. Interestingly, memantine, an FDA-approved drug for AD that acts on NMDA receptors, blocks HMW oligomer-induced cognitive impairment in mice but does not exhibit a beneficial effect on LMW oligomer-induced cognitive impairment (Figueiredo et al., 2013). This example highlights the importance of searching for A β species-specific interventions. A 56-kDa oligomer, A β *₅₆, was recently identified in the brains and CSF of cognitively normal subjects before they developed signs of AD (Amar et al., 2017). Compared to other oligomeric forms of A β , A β *₅₆ triggers a specific intracellular response to augment tau hyperphosphorylation through CaMKII α but not GSK-3 β or Cdk5; this makes A β *₅₆ or its downstream signaling cascades promising targets for early-stage AD interventions (Amar et al., 2017). In addition, because APP processing is regulated by neuronal activity, the manipulation of synaptic transmission is a potential intervention approach to reduce A β load (Cheng, Wu, Geng, & Xiong, 2014). Although the activation of extrasynaptic NMDA receptors mediates excitotoxicity, pharmacological activation of synaptic NMDA receptors enhances α -secretase-mediated APP processing, which in turn shifts the balance towards the non-amyloidogenic pathway (Hoey, Williams, & Perkinson, 2009). This suggests that potentiating synaptic function could have a dual beneficial effect on reversing AD pathogenesis by antagonizing synaptic depression and reducing A β generation.




Fig. 1. A β -induced synaptic failure and excitotoxicity. Presynaptically, A β oligomers enhance calcium influx through VGCC and in turn disrupt the retrograde transport of BDNF. On the other hand, A β facilitates the axonal translation of ATF4 and its transport to cell soma, leading to neurodegeneration. A β also impairs the key processes in synaptic vesicle cycling, including trafficking, release, and recycling. In addition, A β triggers the presynaptic release of D-serine, which acts as the co-agonist of postsynaptic NMDA receptors to mediate synaptotoxicity. Postsynaptically, A β binds extrasynaptic NMDA receptors and induces excitotoxicity, while activation of synaptic NMDA receptors shifts APP processing to the non-amyloidogenic pathways mediated by α -secretase. Furthermore, A β facilitates the removal of AMPA receptors from the synaptic membrane, leading to synaptic depression; this can be prevented by the activation of MC4R and downstream PKA-mediated AMPA receptor phosphorylation. Another GPCR, mGluR5 physically interacts with PrP^c and induces loss of dendritic spines and impaired synaptic functions through Fyn kinase and eEF2. Moreover, A β interacts with cell surface EphB2 receptor and triggers its internalization and degradation. The PDZ-binding motif in the C-terminal of EphB2 is important for antagonizing A β toxicity. In addition, aberrant activation of synaptic EphA4 receptor results in synaptic dysfunction through mechanisms dependent on Cdk5 and c-Abl kinases, which can be attenuated by enhanced interaction with SORLA, an AD genetic risk factor.




Fig. 2. Pathological tau-mediated synaptic dysfunction. At the presynaptic nerve terminal, hyperphosphorylation of tau mediated by kinases such as GSK-3 β and Cdk5 leads to its dissociation from microtubules, concomitant with decreased microtubule stability. In addition, tau competes with the molecular motors dynein and kinesin for microtubule binding, limiting the speed of axonal transport. N-terminal domain of tau activates PP1, which impairs kinesin-mediated axon transport by enhancing GSK-3 β -mediated kinesin phosphorylation. Tau also interacts with synaptic vesicles through Synaptogyrin-3 and impairs presynaptic vesicle cycling. Moreover, missorting of tau to neuronal dendrites causes the disassembly of microtubules through the recruitment of the microtubule-severing enzyme, spastin. Tau infiltration into dendritic spines facilitates A β -induced excitotoxicity through the recruitment of Fyn to the postsynaptic density and phosphorylation of NMDA receptor subunit. In addition, tau phosphorylation by different kinases (e.g., AMPK and p38) can have opposite effects on dendritic spines and synaptic functions. As part of a key process by which tauopathy is spread, trans-synaptic tau propagation is enhanced by synaptic contacts and activity as well as propagation mechanisms independent of synaptic connections.

6.2. Approaches targeting post-translational modifications of tau

Efforts to develop tau-focused therapeutic interventions increased after the finding that in the AD brain, tau load is more closely associated with cognitive decline than A β load (Li & Götz, 2017). Accordingly, approaches aiming to remove pathological tau, prevent tau aggregation, or inhibit pathological post-translational modifications of tau have been developed. Moreover, targeting tau modifications to reduce toxicity, inhibit aggregation, or restore normal subcellular localization is also of particular interest. For example, GSK-3 β transgenic mice exhibit prominent tau hyperphosphorylation and neurodegeneration, while inhibiting GSK-3 β activity by lithium chloride alleviates tauopathy and restores memory functions in AD mouse models (Llorens-Martin, Jurado, Hernandez, & Avila, 2014). Accordingly, clinical trials examining the treatment of AD patients with GSK-3 β inhibitors are underway (del Ser et al., 2013). In addition, EphB2, the receptor tyrosine kinase that mediates synapse maturation, attenuates GSK-3 β -mediated tau phosphorylation by activating the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, providing an easily accessible extracellular target site for inhibiting GSK-3 β activity and tau phosphorylation (Jiang et al., 2015). Thus, multiple mechanisms of tau modification interact with one another and cause tau hyperphosphorylation, providing more avenues to target a specific pathological modification. However, these findings also highlight the difficulties of accurately and specifically targeting tau modification.

6.3. Approaches targeting synaptic receptors

The synaptotoxicity of A β is mediated by a plethora of putative receptor complexes, and multiple approaches have been developed to target these cell surface proteins and their downstream signaling pathways. In particular, in patients with mild cognitive impairment, cognitive performance as assessed by the Mini-Mental State Examination is strongly negatively associated with both GluA3 and GluN2B gene expression; similar negative associations have also been observed for EphA4 and ephrinB2, suggesting that these putative receptor complexes play key roles in mediating disease progression (Berchtold et al., 2014). Furthermore, the activity of these receptors could be modulated extracellularly, making them more accessible targets for AD treatment.

6.3.1. Ionotropic glutamate receptors

Memantine is a noncompetitive NMDA receptor antagonist that preferentially inhibits prolonged extrasynaptic Ca²⁺ influx. It also potently inhibits neuronal excitotoxicity, resulting in symptomatic improvement in moderate-to-severe AD patients (Alam, Lingenfelter, Bender, & Lindsley, 2017). Nitro-memantine is an improved derivative that can selectively block aberrant extrasynaptic NMDA receptor activity and protect neuronal synapses both *in vitro* and *in vivo* (Talantova et al., 2013). As mentioned above, memantine preferentially targets HMW A β -induced synaptotoxicity (Figueiredo et al., 2013). However,

other than its symptom-modifying activity, it remains unclear if memantine can reverse or modify the pathological progression of AD, although it has shown efficacy in mouse models in preclinical studies (Folch et al., 2018). Of note, Chinese medicinal herbs have shown promising results regarding their ability to target glutamate receptor dysfunction in AD at the molecular and cellular levels. Rhynchophylline, a key oxindole alkaloid in the Chinese medicinal herb *Uncaria rhynchophylla*, suppresses the A β -induced activation of extrasynaptic NMDA receptors and restores the impaired LTP and spatial memory in AD model mice (Yang et al., 2018). In addition, anemodiside A3 is a compound isolated from the Chinese medicinal herb *Pulsatilla chinensis*. It potentiates hippocampal LTP and spatial memory as a noncompetitive NMDA receptor modulator and facilitates GluA1 phosphorylation and trafficking to synapses (Ip et al., 2015). However, its role in alleviating the neurodegeneration in AD awaits further investigation. Moreover, the target specificity of herb-derived compounds requires careful consideration.

6.3.2. GPCRs

GPCRs are currently the largest group of drug targets. Our group's pharmacogenetics studies demonstrate that POMC/MC4R counteracts A β -induced synaptic failure by coupling Gs signaling to activate downstream cAMP-dependent mechanisms (Shen et al., 2016). Therefore, manipulating POMC/MC4R activity represents a circuit-specific, disease-modifying approach to alleviating the synaptic deficits in AD. On the other hand, pharmacological inhibition of mGluR5 by its negative or silent allosteric modulator significantly reduces A β load, including plaque deposition and oligomeric A β level, thus preventing synaptic and cognitive impairment in AD. However, the physiological role of mGluR5 in the regulation of glutamatergic transmission remains unaltered, indicating the presence of distinct physiological and pathological pathways (Haas et al., 2017; Hamilton et al., 2016). In addition to the action of mGluR5 at neuronal synapses, mGluR5 is expressed in non-neuronal cells such as microglia and astrocytes where it regulates the release of inflammatory factors and ATP; however, it is uncertain how extracellular A β can activate glial mGluR5 (Biber et al., 1999; Huang et al., 2018; Shrivastava et al., 2013). Nonetheless, mGluR5 likely modulates the process of neurodegeneration in AD by utilizing alternative pathways via glial-neuronal communication (Kumar et al., 2015). Accordingly, developing a disease-modifying strategy based on mGluR5 necessitates an in-depth understanding of its roles in neurons and glia.

6.3.3. Eph receptors

Aberrant hyper- or hypofunction of Eph receptors is prominently associated with synaptic failure or cognitive decline in AD. Screening of approved clinical drug libraries has identified compounds that can specifically inhibit soluble A β binding to EphB2 without affecting A β binding to other receptors or ephrin-B-EphB2 binding (Suzuki, Aimi, Ishihara, & Mizushima, 2016). A synthetic peptide that blocks the EphB2-A β interaction compromises the A β -induced depletion of the surface expression of EphB2 and GluN2B-containing NMDA receptors, with a concomitant improvement in memory performance in AD transgenic mice (Shi et al., 2016).

Peptides and small molecules that antagonize EphA4 receptor activation have also been developed. *In silico* screenings of a Chinese medicinal herb-derived compound library as well as FDA-approved drugs have identified several molecules that inhibit EphA4 activation (Fu et al., 2014; Gu et al., 2018). One of these candidates, rhynchophylline, effectively restores impaired synaptic function in an AD mouse model. Thus, these studies raise the intriguing possibility that specific Eph receptors represent therapeutic targets for AD. However, the receptors and ligands in the Eph/ephrin family share high homology. Therefore, a receptor could respond to multiple ligands or vice versa, making effective and specific drug targeting more challenging.

7. Concluding remarks

Synaptic failure occurs early in AD pathogenesis and is closely associated with cognitive decline, which is the primary symptom of AD. Studies in past decades using AD mouse models and human brain samples have revealed numerous signaling cascades that lead to pathological changes in synapse number, structure, and function. In turn, these efforts have yielded distinct therapeutic approaches to restore the synaptic function in AD animal models. However, none of these approaches have been translated into disease-modifying strategies with clinical applications.

Researchers are only beginning to unravel the pathological mechanisms of synaptic dysfunction in AD. The exact synaptotoxic species of A β and tau as well as the mechanisms underlying their prion-like spreading, the signaling complexes that mediate their initial contact with synapses, and the subsequent deterioration of synapses all remain unknown. Moreover, the specificities of neuronal cell types, synapses, and circuits affected by AD at specific stages also remain unclear. More importantly, most of our understanding of synaptic failure in AD comes from studies of AD mouse models that overexpress specific familial AD risk genes (i.e., *APP*, *PS1*, or *PS2*) or *tau*. Therefore, it is critical to better understand the dysregulation of synaptic signaling and synaptic failure in sporadic AD, which accounts for 95% of AD cases. In-depth investigations of the molecular and cellular mechanisms of synaptotoxicity are still needed to develop synapse-centered, disease-modifying treatments for AD as well as precision medicine aiming to systematically categorize the causes of synaptic failure in AD.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Acknowledgments

We apologize to the many authors whose excellent studies were not cited in this review because of space limitations. We thank Ka-Chun Lok for his help preparing figures. The studies by Y. Chen, A.K.Y. Fu, and N.Y. Ip were supported in part by the Hong Kong Research Council Theme-based Research Schemes (T13/605-18-W), the Shenzhen Knowledge Innovation Program (JCYJ20151030140325152, JCYJ20160428145818099, JCYJ20170413165053031, JCYJ20151030154629774), the Areas of Excellence Scheme of the University Grants Committee (AoE/M-604/16), the Research Grants Council of Hong Kong SAR (C6003-14G), the National Natural Science Foundation of China (31671047), the External Cooperation Program of Chinese Academy of Sciences (172644KYSB20160026), the S.H. Ho Foundation, and the University Lodge of Hong Kong (ULHK15SC01).

References

- Abramov, E., Dolev, I., Fogel, H., Ciccostoto, G. D., Ruff, E., & Slutsky, I. (2009). Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. *Nature Neuroscience* *12*, 1567–1576.
- Alam, R., Driver, D., Wu, S., Lozano, E., Key, S. L., Hole, J. T., ... Lu, J. (2017). Preclinical characterization of an antibody [LY3303560] targeting aggregated tau. *Alzheimers Dement* *13*(Supplement), 592–593.
- Alam, S., Lingenfelter, K. S., Bender, A. M., & Lindsley, C. W. (2017). Classics in chemical neuroscience: Memantine. *ACS Chemical Neuroscience* *8*, 1823–1829.
- Amar, F., Sherman, M. A., Rush, T., Larson, M., Boyle, G., Chang, L., ... Lesne, S. E. (2017). The amyloid-beta oligomer Abeta*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. *Science Signaling* *10*.
- Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., ... Ikezu, T. (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation. *Nature Neuroscience* *18*, 1584–1593.
- Baleriola, J., Walker, C. A., Jean, Y. Y., Crary, J. F., Troy, C. M., Nagy, P. L., & Hengst, U. (2014). Axonally synthesized ATF4 transmits a neurodegenerative signal across brain regions. *Cell* *158*, 1159–1172.
- Berchtold, N. C., Sabbagh, M. N., Beach, T. G., Kim, R. C., Cribbs, D. H., & Cotman, C. W. (2014). Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. *Neurobiology of Aging* *35*, 1961–1972.

- Biber, K., Laurie, D. J., Berthele, A., Sommer, B., Tolle, T. R., Gebicke-Harter, P. J., ... Boddeke, H. W. (1999). Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. *Journal of Neurochemistry* 72, 1671–1680.
- Biemans, E. A., Verhoeven-Duif, N. M., Gerrits, J., Claassen, J. A., Kuiperij, H. B., & Verbeek, M. M. (2016). CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls. *Neurobiology of Aging* 42, 213–216.
- Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kwas, C., ... Gylys, K. H. (2016). Synaptic amyloid-beta oligomers precede p-Tau and differentiate high pathology control cases. *The American Journal of Pathology* 186, 185–198.
- Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nature Reviews. Neurology* 6, 131–144.
- Bourgin, C., Murai, K. K., Richter, M., & Pasquale, E. B. (2007). The EphA4 receptor regulates dendritic spine remodeling by affecting beta1-integrin signaling pathways. *The Journal of Cell Biology* 178, 1295–1307.
- Braak, H., & Braak, E. (1995). Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging* 16, 271–278 (discussion 278–284).
- Brito-Moreira, J., Paula-Lima, A. C., Bomfim, T. R., Oliveira, F. B., Sepulveda, F. J., De Mello, F. G., ... Ferreira, S. T. (2011). Abeta oligomers induce glutamate release from hippocampal neurons. *Current Alzheimer Research* 8, 552–562.
- Calafate, S., Buist, A., Miskiewicz, K., Vijayan, V., Daneels, G., de Strooper, B., ... Moechars, D. (2015). Synaptic contacts enhance cell-to-cell tau pathology propagation. *Cell Reports* 11, 1176–1183.
- Calafate, S., Flavin, W., Verstreken, P., & Moechars, D. (2016). Loss of Bin1 promotes the propagation of tau pathology. *Cell Reports* 17, 931–940.
- de Calignon, A., Polydoro, M., Suarez-Calvet, M., Williams, C., Adamowicz, D. H., Kopeikina, K. J., ... Hyman, B. T. (2012). Propagation of tau pathology in a model of early Alzheimer's disease. *Neuron* 73, 685–697.
- Chang, E. H., Savage, M. J., Flood, D. G., Thomas, J. M., Levy, R. B., Mahadomrongkul, V., ... Huerta, P. T. (2006). AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. *Proceedings of the National Academy of Sciences of the United States of America* 103, 3410–3415.
- Chater, T. E., & Goda, Y. (2014). The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity. *Frontiers in Cellular Neuroscience* 8, 401.
- Chen, Y., Fu, A. K., & Ip, N. Y. (2012). Eph receptors at synapses: Implications in neurodegenerative diseases. *Cellular Signalling* 24, 606–611.
- Cheng, X., Wu, J., Geng, M., & Xiong, J. (2014). Role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease. *Neurobiology of Aging* 35, 1217–1232.
- Cisse, M., Halabisky, B., Harris, J., Devidze, N., Dubal, D. B., Sun, B., ... Mucke, L. (2011). Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. *Nature* 469, 47–52.
- Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R. A., Frank, S., Hench, J., ... Tolnay, M. (2013). Brain homogenates from human tauopathies induce tau inclusions in mouse brain. *Proceedings of the National Academy of Sciences of the United States of America* 110, 9535–9540.
- Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018). Alzheimer's disease drug development pipeline: 2018. *Alzheimers Dement (N Y)* 4, 195–214.
- Das, B., & Yan, R. (2017). Role of BACE1 in Alzheimer's synaptic function. *Transl Neurodegener* 6, 23.
- De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007). Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. *The Journal of Biological Chemistry* 282, 11590–11601.
- Decker, H., Jurgensen, S., Adrover, M. F., Brito-Moreira, J., Bomfim, T. R., Klein, W. L., ... Ferreira, S. T. (2010). N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-beta peptide oligomers. *Journal of Neurochemistry* 115, 1520–1529.
- Decker, H., Lo, K. Y., Unger, S. M., Ferreira, S. T., & Silverman, M. A. (2010). Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. *The Journal of Neuroscience* 30, 9166–9171.
- Decker, J. M., Kruger, L., Sydow, A., Zhao, S., Frotscher, M., Mandelkow, E., & Mandelkow, E. M. (2015). Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca(++) dysregulation. *Acta Neuropathologica Communications* 3, 23.
- DeVos, S. L., Corjuc, B. T., Oakley, D. H., Nobuhara, C. K., Bannon, R. N., Chase, A., ... Hyman, B. T. (2018). Synaptic tau seeding precedes tau pathology in human Alzheimer's disease brain. *Frontiers in Neuroscience* 12, 267.
- Dewar, D., Chalmers, D. T., Graham, D. I., & McCulloch, J. (1991). Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: An autoradiographic study of the hippocampus. *Brain Research* 553, 58–64.
- Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. (2008). Differential regulation of dynein and kinesin motor proteins by tau. *Science* 319, 1086–1089.
- Doody, R. (2017). Developing disease-modifying treatments in Alzheimer's disease - A perspective from Roche and Genentech. *The Journal of Prevention of Alzheimer's Disease* 4, 264–272.
- Fa, M., Puzzo, D., Piacentini, R., Staniszewski, A., Zhang, H., Baltrons, M. A., ... Arancio, O. (2016). Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. *Scientific Reports* 6, 19393.
- Ferreira, S. T., & Klein, W. L. (2011). The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. *Neurobiology of Learning and Memory* 96, 529–543.
- Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015). Soluble amyloid-beta oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. *Frontiers in Cellular Neuroscience* 9, 191.
- Figueiredo, C. P., Clarke, J. R., Ledo, J. H., Ribeiro, F. C., Costa, C. V., Melo, H. M., ... Ferreira, S. T. (2013). Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers. *The Journal of Neuroscience* 33, 9626–9634.
- Filosa, A., Paixao, S., Honsek, S. D., Carmona, M. A., Becker, L., Feddersen, B., ... Klein, R. (2009). Neuron-glia communication via EphA4/ephrin-A3 modulates LTP through glial glutamate transport. *Nature Neuroscience* 12, 1285–1292.
- Fogel, H., Frere, S., Segev, O., Bharill, S., Shapira, I., Gazit, N., ... Slutsky, I. (2014). APP homodimers transduce an amyloid-beta-mediated increase in release probability at excitatory synapses. *Cell Reports* 7, 1560–1576.
- Folch, J., Busquets, O., Etxcheto, M., Sanchez-Lopez, E., Castro-Torres, R. D., Verdaguer, E., ... Camins, A. (2018). Memantine for the treatment of dementia: A review on its current and future applications. *Journal of Alzheimer's Disease* 62, 1223–1240.
- Forner, S., Baglietto-Vargas, D., Martini, A. C., Trujillo-Estrada, L., & LaFerla, F. M. (2017). Synaptic impairment in ALZHEIMER'S disease: A dysregulated symphony. *Trends in Neurosciences* 40, 347–357.
- Frandemiche, M. L., De Seranno, S., Rush, T., Borel, E., Elie, A., Arnal, I., ... Buisson, A. (2014). Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers. *The Journal of Neuroscience* 34, 6084–6097.
- Fu, A. K., Hung, K. W., Fu, W. Y., Shen, C., Chen, Y., Xia, J., ... Ip, N. Y. (2011). APC(Cdh1) mediates EphA4-dependent downregulation of AMPA receptors in homeostatic plasticity. *Nature Neuroscience* 14, 181–189.
- Fu, A. K., Hung, K. W., Huang, H., Gu, S., Shen, Y., Cheng, E. Y., ... Ip, N. Y. (2014). Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America* 111, 9959–9964.
- Fu, A. K., & Ip, N. Y. (2017). Regulation of postsynaptic signaling in structural synaptic plasticity. *Current Opinion in Neurobiology* 45, 148–155.
- Fu, W. Y., Chen, Y., Sahin, M., Zhao, X. S., Shi, L., Bikoff, J. B., ... Ip, N. Y. (2007). Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. *Nature Neuroscience* 10, 67–76.
- Gan, K. J., & Silverman, M. A. (2015). Dendritic and axonal mechanisms of Ca2+ elevation impair BDNF transport in Abeta oligomer-treated hippocampal neurons. *Molecular Biology of the Cell* 26, 1058–1071.
- Gauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., ... Wischik, C. M. (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet* 388, 2873–2884.
- Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017). Propagation of tau aggregates and neurodegeneration. *Annual Review of Neuroscience* 40, 189–210.
- Gorsky, M. K., Burnouf, S., Dols, J., Mandelkow, E., & Partridge, L. (2016). Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. *Scientific Reports* 6, 22685.
- Gorsky, M. K., Burnouf, S., Sofola-Adesakin, O., Dols, J., Augustin, H., Weigelt, C. M., ... Partridge, L. (2017). Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity. *Scientific Reports* 7, 9984.
- Greger, I. H., Ziff, E. B., & Penn, A. C. (2007). Molecular determinants of AMPA receptor subunit assembly. *Trends in Neurosciences* 30, 407–416.
- Gu, S., Fu, W. Y., Fu, A. K. Y., Tong, E. P. S., Ip, F. C. F., Huang, X., & Ip, N. Y. (2018). Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs. *Scientific Reports* 8, 7377.
- Guntupalli, S., Jang, S. E., Zhu, T., Haganir, R. L., Widagdo, J., & Anggono, V. (2017). GluA1 subunit ubiquitination mediates amyloid-beta-induced loss of surface alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. *The Journal of Biological Chemistry* 292, 8186–8194.
- Guntupalli, S., Widagdo, J., & Anggono, V. (2016). Amyloid-beta-induced dysregulation of AMPA receptor trafficking. *Neural Plasticity* 2016, 3204519.
- Haas, L. T., Kostylev, M. A., & Strittmatter, S. M. (2014). Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPc) and metabotropic glutamate receptor 5 (mGluR5). *The Journal of Biological Chemistry* 289, 28460–28477.
- Haas, L. T., Salazar, S. V., Kostylev, M. A., Um, J. W., Kaufman, A. C., & Strittmatter, S. M. (2016). Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease. *Brain* 139, 526–546.
- Haas, L. T., Salazar, S. V., Smith, L. M., Zhao, H. R., Cox, T. O., Herber, C. S., ... Strittmatter, S. M. (2017). Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer's mouse phenotypes. *Cell Reports* 20, 76–88.
- Hamilton, A., Esseltine, J. L., DeVries, R. A., Cregan, S. P., & Ferguson, S. S. (2014). Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. *Molecular Brain* 7, 40.
- Hamilton, A., Vasefi, M., Vander Tuin, C., McQuaid, R. J., Anisman, H., & Ferguson, S. S. (2016). Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model. *Cell Reports* 15, 1859–1865.
- Hanger, D. P., Anderton, B. H., & Noble, W. (2009). Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. *Trends in Molecular Medicine* 15, 112–119.
- Hanger, D. P., & Noble, W. (2011). Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. *International Journal of Alzheimer's Disease* 2011, 352805.
- Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science* 297, 353–356.
- Harney, S. C., Rowan, M., & Anwyl, R. (2006). Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium buffering. *The Journal of Neuroscience* 26, 1128–1132.
- Henkemeyer, M., Itkiss, O. S., Ngo, M., Hickmott, P. W., & Ethell, I. M. (2003). Multiple EphB receptor tyrosine kinases shape dendritic spines in the hippocampus. *The Journal of Cell Biology* 163, 1313–1326.

- Hoey, S. E., Williams, R. J., & Perkinson, M. S. (2009). Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. *The Journal of Neuroscience* 29, 4442–4460.
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., ... Siemers, E. (2018). Trial of solanezumab for mild dementia Due to Alzheimer's disease. *The New England Journal of Medicine* 378, 321–330.
- Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., ... Liao, D. (2010). Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. *Neuron* 68, 1067–1081.
- Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., & Malinow, R. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. *Neuron* 52, 831–843.
- Hu, N. W., Nicoll, A. J., Zhang, D., Mably, A. J., O'Malley, T., Purro, S. A., ... Rowan, M. J. (2014). mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. *Nature Communications* 5, 3374.
- Hu, R., Wei, P., Jin, L., Zheng, T., Chen, W. Y., Liu, X. Y., ... Gao, C. (2017). Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model. *Cell Death & Disease* 8, e2717.
- Huang, T. Y., Zhao, Y., Jiang, L. L., Li, X., Liu, Y., Sun, Y., ... Xu, H. (2017). SORLA attenuates EphA4 signaling and amyloid beta-induced neurodegeneration. *The Journal of Experimental Medicine* 214, 3669–3685.
- Huang, Y. Y., Zhang, Q., Zhang, J. N., Zhang, Y. N., Gu, L., Yang, H. M., ... Zhang, H. (2018). Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson's disease. *Brain, Behavior, and Immunity* 71, 93–107.
- Inoue, E., Deguchi-Tawarada, M., Togawa, A., Matsui, C., Arita, K., Katahira-Tayama, S., ... Takai, Y. (2009). Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4 and dendritic spine formation. *The Journal of Cell Biology* 185, 551–564.
- Ip, F. C., Fu, W. Y., Cheng, E. Y., Tong, E. P., Lok, K. C., Liang, Y., ... Ip, N. Y. (2015). Anemoside A3 enhances cognition through the regulation of synaptic function and neuroprotection. *Neuropsychopharmacology* 40, 1877–1887.
- Iltner, A., Chua, S. W., Bertz, J., Volkerling, A., van der Hoven, J., Gladbach, A., ... Iltner, L. M. (2016). Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer's mice. *Science* 354, 904–908.
- Iltner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., ... Gotz, J. (2010). Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. *Cell* 142, 387–397.
- Jiang, J., Wang, Z. H., Qu, M., Gao, D., Liu, X. P., Zhu, L. Q., & Wang, J. Z. (2015). Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3beta. *Scientific Reports* 5, 11765.
- Kadavath, H., Hofele, R. V., Biernat, J., Kumar, S., Tepper, K., Urlaub, H., ... Zweckstetter, M. (2015). Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. *Proceedings of the National Academy of Sciences of the United States of America* 112, 7501–7506.
- Kanaan, N. M., Morfini, G., Pigino, G., LaPointe, N. E., Andreadis, A., Song, Y., ... Brady, S. T. (2012). Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. *Neurobiology of Aging* 33, 826 e815–830.
- Kanaan, N. M., Morfini, G. A., LaPointe, N. E., Pigino, G. F., Patterson, K. R., Song, Y., ... Binder, L. I. (2011). Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. *The Journal of Neuroscience* 31, 9858–9868.
- Kandimala, R. J., Prabhakar, S., Wani, W. Y., Kaushal, A., Gupta, N., Sharma, D. R., ... Gill, K. D. (2013). CSF p-Tau levels in the prediction of Alzheimer's disease. *Biol Open* 2, 1119–1124.
- Kania, A., & Klein, R. (2016). Mechanisms of ephrin-Eph signalling in development, physiology and disease. *Nature Reviews. Molecular Cell Biology* 17, 240–256.
- Kaufman, S. K., Sanders, D. W., Thomas, T. L., Ruchinskas, A. J., Vaquer-Alicea, J., Sharma, A. M., ... Diamond, M. I. (2016). Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. *Neuron* 92, 796–812.
- Kayser, M. S., Nolt, M. J., & Dalva, M. B. (2008). EphB receptors couple dendritic filopodia motility to synapse formation. *Neuron* 59, 56–69.
- Kim, H. Y., Kim, H. V., Jo, S., Lee, C. J., Choi, S. Y., Kim, D. J., & Kim, Y. (2015). EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-beta oligomers and plaques. *Nature Communications* 6, 8997.
- Kim, Y., Choi, H., Lee, W., Park, H., Kam, T. I., Hong, S. H., ... Jung, Y. K. (2016). Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. *Neurobiology of Disease* 87, 19–28.
- Kimura, T., Ishiguro, K., & Hisanaga, S. (2014). Physiological and pathological phosphorylation of tau by Cdk5. *Frontiers in Molecular Neuroscience* 7, 65.
- Klementieva, O., Willen, K., Martinsson, I., Israelsson, B., Engdahl, A., Cladera, J., ... Gouras, G. K. (2017). Pre-plaque conformational changes in Alzheimer's disease-linked Abeta and APP. *Nature Communications* 8, 14726.
- Knafo, S., Sanchez-Puelles, C., Palomer, E., Delgado, I., Draffin, J. E., Mingo, J., ... Esteban, J. A. (2016). PTEN recruitment controls synaptic and cognitive function in Alzheimer's models. *Nature Neuroscience* 19, 443–453.
- Knight, R., Khondoker, M., Magill, N., Stewart, R., & Landau, S. (2018). A Systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. *Dementia and Geriatric Cognitive Disorders* 45, 131–151.
- Koelsch, G. (2017). BACE1 function and inhibition: Implications of intervention in the amyloid pathway of Alzheimer's disease pathology. *Molecules*, 22.
- Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., ... Spire-Jones, T. L. (2009). Oligomeric amyloid beta associates with post-synaptic densities and correlates with excitatory synapse loss near senile plaques. *Proceedings of the National Academy of Sciences of the United States of America* 106, 4012–4017.
- Krashes, M. J., Lowell, B. B., & Garfield, A. S. (2016). Melanocortin-4 receptor-regulated energy homeostasis. *Nature Neuroscience* 19, 206–219.
- Kumar, A., Dhull, D. K., & Mishra, P. S. (2015). Therapeutic potential of mGluR5 targeting in Alzheimer's disease. *Frontiers in Neuroscience* 9, 215.
- del Ser, T., Steinwachs, K. C., Gertz, H. J., Andres, M. V., Gomez-Carrillo, B., Medina, M., ... Leon, T. (2013). Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglistib: A pilot study. *Journal of Alzheimer's Disease* 33, 205–215.
- Li, C., & Götz, J. (2017). Tau-based therapies in neurodegeneration: Opportunities and challenges. *Nature Reviews. Drug Discovery* 16, 863–883.
- Li, S., Hong, S., Sheppardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. *Neuron* 62, 788–801.
- Li, S., Jin, M., Koelschperger, T., Sheppardson, N. E., Shankar, G. M., & Selkoe, D. J. (2011). Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. *The Journal of Neuroscience* 31, 6627–6638.
- Li, X., Kumar, Y., Zempel, H., Mandelkow, E. M., Biernat, J., & Mandelkow, E. (2011). Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. *The EMBO Journal* 30, 4825–4837.
- Litterst, C., Georgakopoulos, A., Shioi, J., Gheri, E., Wisniewski, T., Wang, R., ... Robakis, N. K. (2007). Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. *The Journal of Biological Chemistry* 282, 16155–16163.
- Liu, S. J., Gasperini, R., Foa, L., & Small, D. H. (2010). Amyloid-beta decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2. *Journal of Alzheimer's Disease* 21, 655–666.
- Llorens-Martin, M., Jurado, J., Hernandez, F., & Avila, J. (2014). GSK-3beta, a pivotal kinase in Alzheimer disease. *Frontiers in Molecular Neuroscience* 7, 46.
- Madeira, C., Lourenco, M. V., Vargas-Lopes, C., Suemoto, C. K., Brandao, C. O., Reis, T., ... Panizzutti, R. (2015). d-serine Levels in Alzheimer's disease: Implications for novel biomarker development. *Translational Psychiatry* 5, e561.
- Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., & Polleux, F. (2013). The CAMKK2-AMPA kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. *Neuron* 78, 94–108.
- Martineau, M., Parpura, V., & Mothet, J. P. (2014). Cell-type specific mechanisms of D-serine uptake and release in the brain. *Front Synaptic Neurosci* 6, 12.
- Matsui, C., Inoue, E., Kakita, A., Arita, K., Deguchi-Tawarada, M., Togawa, A., ... Takahashi, H. (2012). Involvement of the gamma-secretase-mediated EphA4 signaling pathway in synaptic pathogenesis of Alzheimer's disease. *Brain Pathology* 22, 776–787.
- McInnes, J., Wierda, K., Snellinx, A., Bounti, L., Wang, Y. C., Stancu, I. C., ... Verstreken, P. (2018). Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. *Neuron* 97(823–835), e828.
- Min, S. W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., ... Gan, L. (2015). Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. *Nature Medicine* 21, 1154–1162.
- Min, S. W., Sohn, P. D., Li, Y., Devidze, N., Johnson, J. R., Krogan, N. J., ... Gan, L. (2018). SIRT1 deacetylates tau and reduces pathogenic tau spread in a mouse model of tauopathy. *The Journal of Neuroscience* 38, 3680–3688.
- Minano-Molina, A. J., Espana, J., Martin, E., Barneda-Zahonero, B., Fado, R., Sole, M., ... Rodriguez-Alvarez, J. (2011). Soluble oligomers of amyloid-beta peptide disrupt membrane trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction. *The Journal of Biological Chemistry* 286, 27311–27321.
- Miyamoto, T., Kim, D., Knox, J. A., Johnson, E., & Mucke, L. (2016). Increasing the receptor tyrosine kinase EphB2 prevents amyloid-beta-induced depletion of cell surface glutamate receptors by a mechanism that requires the PDZ-binding Motif of EphB2 and neuronal activity. *The Journal of Biological Chemistry* 291, 1719–1734.
- Moreno, H., Choi, S., Yu, E., Brusco, J., Avila, J., Moreira, J. E., ... Llinas, R. R. (2011). Blocking effects of human tau on squid giant synapse transmission and its prevention by T-817 MA. *Front Synaptic Neurosci* 3, 3.
- Moreno, H., Morfini, G., Buitrago, L., Ujlaki, G., Choi, S., Yu, E., ... Llinas, R. R. (2016). Tau pathology-mediated presynaptic dysfunction. *Neuroscience* 325, 30–38.
- Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011). The many faces of tau. *Neuron* 70, 410–426.
- Murai, K. K., Nguyen, L. N., Irie, F., Yamaguchi, Y., & Pasquale, E. B. (2003). Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. *Nature Neuroscience* 6, 153–160.
- Murata, Y., & Constantine-Paton, M. (2013). Postsynaptic density scaffold SAP102 regulates cortical synapse development through EphB and PAK signaling pathway. *The Journal of Neuroscience* 33, 5040–5052.
- Niewidok, B., Igaev, M., Sundermann, F., Janning, D., Bakota, L., & Brandt, R. (2016). Presence of a carboxy-terminal pseudorepeat and disease-like pseudohyperphosphorylation critically influence tau's interaction with microtubules in axon-like processes. *Molecular Biology of the Cell* 27, 3537–3549.
- Nistico, R., Pignatelli, M., Piccinin, S., Mercuri, N. B., & Collingridge, G. (2012). Targeting synaptic dysfunction in Alzheimer's disease therapy. *Molecular Neurobiology* 46, 572–587.
- Ovsepian, S. V., O'Leary, V. B., Zaborszky, L., Ntzachristos, V., & Dolly, J. O. (2018). Synaptic vesicle cycle and amyloid beta: Biting the hand that feeds. *Alzheimers Dement* 14, 502–513.
- Palop, J. J., & Mucke, L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. *Nature Neuroscience* 13, 812–818.
- Park, J., Jang, M., & Chang, S. (2013). Deleterious effects of soluble amyloid-beta oligomers on multiple steps of synaptic vesicle trafficking. *Neurobiology of Disease* 55, 129–139.

- Pickett, E. K., Koffie, R. M., Wegmann, S., Henstridge, C. M., Herrmann, A. G., Colom-Cadena, M., ... Spires-Jones, T. L. (2016). Non-fibrillar oligomeric amyloid-beta within synapses. *Journal of Alzheimer's Disease* 53, 787–800.
- Pigino, G., Morfini, G., Atagi, Y., Deshpande, A., Yu, C., Jungbauer, L., ... Brady, S. (2009). Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. *Proceedings of the National Academy of Sciences of the United States of America* 106, 5907–5912.
- Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008). Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. *The Journal of Neuroscience* 28, 14537–14545.
- Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer's disease. *The New England Journal of Medicine* 362, 329–344.
- Ramsar, E. M., Gan, K. J., Decker, H., Fan, E. Y., Suzuki, M. M., Ferreira, S. T., & Silverman, M. A. (2013). Amyloid-beta oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. *Molecular Biology of the Cell* 24, 2494–2505.
- Reinders, N. R., Pao, Y., Renner, M. C., da Silva-Matos, C. M., Lodder, T. R., Malinow, R., & Kessels, H. W. (2016). Amyloid-beta effects on synapses and memory require AMPA receptor subunit GluA3. *Proceedings of the National Academy of Sciences of the United States of America* 113, E6526–E6534.
- Reiner, A., & Levitz, J. (2018). Glutamatergic signaling in the central nervous system: Ionotropic and metabotropic receptors in concert. *Neuron* 98, 1080–1098.
- Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010). Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. *Neuron* 66, 739–754.
- Roberson, E. D., Halabisky, B., Yoo, J. W., Yao, J., Chin, J., Yan, F., ... Mucke, L. (2011). Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. *The Journal of Neuroscience* 31, 700–711.
- Rosenberger, A. F., Rozemuller, A. J., van der Flier, W. M., Scheltens, P., van der Vies, S. M., & Hoozemans, J. J. (2014). Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. *Acta Neuropathologica Communications* 2, 79.
- Sala Frigerio, C., & De Strooper, B. (2016). Alzheimer's disease mechanisms and emerging roads to novel therapeutics. *Annual Review of Neuroscience* 39, 57–79.
- Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., ... Diamond, M. I. (2014). Distinct tau prion strains propagate in cells and mice and define different tauopathies. *Neuron* 82, 1271–1288.
- Scheefhals, N., & MacGillivray, H. D. (2018). Functional organization of postsynaptic glutamate receptors. *Molecular and Cellular Neurosciences* 91, 82–94.
- Sen, T., Saha, P., & Sen, N. (2018). Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-beta. *Science Signaling*, 11.
- Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., ... Panza, F. (2016). Tau-directed approaches for the treatment of Alzheimer's disease: Focus on leuco-methylthionium. *Expert Review of Neurotherapeutics* 16, 259–277.
- Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P. H., Williams, L., Maier, M., ... Sandrock, A. (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. *Nature* 537, 50–56.
- Shen, Y., Fu, W. Y., Cheng, E. Y., Fu, A. K., & Ip, N. Y. (2013). Melanocortin-4 receptor regulates hippocampal synaptic plasticity through a protein kinase A-dependent mechanism. *The Journal of Neuroscience* 33, 464–472.
- Shen, Y., Tian, M., Zheng, Y., Gong, F., Fu, A. K. Y., & Ip, N. Y. (2016). Stimulation of the hippocampal POMC/MC4R circuit alleviates synaptic plasticity impairment in an Alzheimer's disease model. *Cell Reports* 17, 1819–1831.
- Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012). Synapses and Alzheimer's disease. *Cold Spring Harbor Perspectives in Biology*, 4.
- Shi, X. D., Sun, K., Hu, R., Liu, X. Y., Hu, Q. M., Sun, X. Y., ... Gao, C. (2016). Blocking the interaction between EphB2 and ADDLs by a small peptide rescues impaired synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease. *The Journal of Neuroscience* 36, 11959–11973.
- Shrivastava, A. N., Kowalewski, J. M., Renner, M., Bousset, L., Koulakoff, A., Melki, R., ... Triller, A. (2013). beta-amyloid and ATP-induced diffusional trapping of astrocyte and neuronal metabotropic glutamate type-5 receptors. *Glia* 61, 1673–1686.
- Simon, A. M., de Maturana, R. L., Ricobaraza, A., Escibano, L., Schiapparelli, L., Cuadrado-Tejedor, M., ... Frechilla, D. (2009). Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. *Journal of Alzheimer's Disease* 17, 773–786.
- Sohn, P. D., Tracy, T. E., Son, H. I., Zhou, Y., Leite, R. E., Miller, B. L., ... Gan, L. (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. *Molecular Neurodegeneration* 11, 47.
- Sosa, L. J., Caceres, A., Dupraz, S., Oksdath, M., Quiroga, S., & Lorenzo, A. (2017). The physiological role of the amyloid precursor protein as an adhesion molecule in the developing nervous system. *Journal of Neurochemistry* 143, 11–29.
- Spillantini, M. G., & Goedert, M. (2013). Tau pathology and neurodegeneration. *Lancet Neurology* 12, 609–622.
- Stern, J. L., Lessard, D. V., Hoeprich, G. J., Morfini, G. A., & Berger, C. L. (2017). Phosphoregulation of Tau modulates inhibition of kinesin-1 motility. *Molecular Biology of the Cell* 28, 1079–1087.
- Suberbielle, E., Djukic, B., Evans, M., Kim, D. H., Taneja, P., Wang, X., ... Mucke, L. (2015). DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. *Nature Communications* 6, 8897.
- Suzuki, K., Aimi, T., Ishihara, T., & Mizushima, T. (2016). Identification of approved drugs that inhibit the binding of amyloid beta oligomers to ephrin type-B receptor 2. *FEBS Open Bio* 6, 461–468.
- Swanson, E., Breckenridge, L., McMahon, L., Som, S., McConnell, I., & Bloom, G. S. (2017). Extracellular tau oligomers induce invasion of endogenous tau into the somatodendritic compartment and axonal transport dysfunction. *Journal of Alzheimer's Disease* 58, 803–820.
- Tackenberg, C., Grinschgl, S., Trutzel, A., Santuccione, A. C., Frey, M. C., Konietzko, U., ... Nitsch, R. M. (2013). NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. *Cell Death & Disease* 4, e608.
- Tai, H. C., Wang, B. Y., Serrano-Pozo, A., Frosch, M. P., Spires-Jones, T. L., & Hyman, B. T. (2014). Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimer's disease. *Acta Neuropathologica Communications* 2, 146.
- Takeda, S., Wegmann, S., Cho, H., DeVos, S. L., Commins, C., Roe, A. D., ... Hyman, B. T. (2015). Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. *Nature Communications* 6, 8490.
- Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S., ... Lipton, S. A. (2013). Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proceedings of the National Academy of Sciences of the United States of America* 110, E2518–E2527.
- Tracy, T. E., Sohn, P. D., Minami, S. S., Wang, C., Min, S. W., Li, Y., ... Gan, L. (2016). Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. *Neuron* 90, 245–260.
- Trzeciakiewicz, H., Tseng, J. H., Wander, C. M., Madden, V., Tripathy, A., Yuan, C. X., & Cohen, T. J. (2017). A dual pathogenic mechanism links tau acetylation to sporadic tauopathy. *Scientific Reports* 7, 44102.
- Tsushima, H., Emanuele, M., Polenghi, A., Esposito, A., Vassalli, M., Barberis, A., ... Chiergatti, E. (2015). HDAC6 and RhoA are novel players in Abeta-driven disruption of neuronal polarity. *Nature Communications* 6, 7781.
- Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014). Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease. *Molecular Neurodegeneration* 9, 48.
- Um, J. W., Kaufman, A. C., Kostylev, M., Heiss, J. K., Stagi, M., Takahashi, H., ... Strittmatter, S. M. (2013). Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. *Neuron* 79, 887–902.
- Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., ... Strittmatter, S. M. (2012). Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. *Nature Neuroscience* 15, 1227–1235.
- Vargas, L. M., Leal, N., Estrada, L. D., Gonzalez, A., Serrano, F., Araya, K., ... Alvarez, A. R. (2014). EphA4 activation of c-Abl mediates synaptic loss and LTP blockade caused by amyloid-beta oligomers. *PLoS One* 9, e92309.
- Vassar, R. (2014). BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. *Alzheimer's Research & Therapy* 6, 89.
- Velasco, P. T., Heffern, M. C., Sebollela, A., Popova, I. A., Lacor, P. N., Lee, K. B., ... Klein, W. L. (2012). Synapse-binding subpopulations of Abeta oligomers sensitive to peptide assembly blockers and scFv antibodies. *ACS Chemical Neuroscience* 3, 972–981.
- Waites, C. L., Craig, A. M., & Garner, C. C. (2005). Mechanisms of vertebrate synaptogenesis. *Annual Review of Neuroscience* 28, 251–274.
- Wang, Y., & Mandelkow, E. (2016). Tau in physiology and pathology. *Nature Reviews. Neuroscience* 17, 5–21.
- Wegmann, S., Maury, E. A., Kirk, M. J., Saqrán, L., Roe, A., DeVos, S. L., ... Hyman, B. T. (2015). Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. *The EMBO Journal* 34, 3028–3041.
- West, T., Hu, Y., Verghese, P. B., Bateman, R. J., Braunstein, J. B., Fogelman, I., ... Holtzman, D. M. (2017). Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies. *The Journal of Prevention of Alzheimer's Disease* 4, 236–241.
- de Wilde, M. C., Overk, C. R., Sijben, J. W., & Masliah, E. (2016). Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. *Alzheimer's Dement* 12, 633–644.
- Wu, J. W., Herman, M., Liu, L., Simoes, S., Acker, C. M., Figueroa, H., ... Duff, K. E. (2013). Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. *The Journal of Biological Chemistry* 288, 1856–1870.
- Wu, J. W., Hussaini, S. A., Bastille, I. M., Rodriguez, G. A., Mrejeru, A., Rielett, K., ... Duff, K. E. (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. *Nature Neuroscience* 19, 1085–1092.
- Xia, D., Li, C., & Gotz, J. (2015). Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. *Biochimica et Biophysica Acta* 1852, 913–924.
- Xia, M., Cheng, X., Yi, R., Gao, D., & Xiong, J. (2016). The binding receptors of Abeta: An alternative therapeutic target for Alzheimer's disease. *Molecular Neurobiology* 53, 455–471.
- Xu, J., Litterst, C., Georgakopoulos, A., Zaganas, I., & Robakis, N. K. (2009). Peptide EphB2/CTF2 generated by the gamma-secretase processing of EphB2 receptor promotes tyrosine phosphorylation and cell surface localization of N-methyl-D-aspartate receptors. *The Journal of Biological Chemistry* 284, 27220–27228.
- Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., ... Holtzman, D. M. (2013). Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. *Neuron* 80, 402–414.
- Yang, T., Li, S., Xu, H., Walsh, D. M., & Selkoe, D. J. (2017). Large soluble oligomers of amyloid beta-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate. *The Journal of Neuroscience* 37, 152–163.
- Yang, Y., Ji, W. G., Zhu, Z. R., Wu, Y. L., Zhang, Z. Y., & Qu, S. C. (2018). Rhynchophylline suppresses soluble Abeta1–42-induced impairment of spatial cognition function via inhibiting excessive activation of extrasynaptic NR2B-containing NMDA receptors. *Neuropharmacology* 135, 100–112.
- Yasuda, R. P., Ikonomic, M. D., Sheffield, R., Rubin, R. T., Wolfe, B. B., & Armstrong, D. M. (1995). Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: A biochemical study. *Brain Research* 678, 161–167.

- Ye, X., Feng, T., Tammineni, P., Chang, Q., Jeong, Y. Y., Margolis, D. J., ... Cai, Q. (2017). Regulation of synaptic amyloid-beta generation through BACE1 retrograde transport in a mouse model of Alzheimer's disease. *The Journal of Neuroscience* 37, 2639–2655.
- Yin, Y., Gao, D., Wang, Y., Wang, Z. H., Wang, X., Ye, J., ... Wang, J. Z. (2016). Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling. *Proceedings of the National Academy of Sciences of the United States of America* 113, E3773–E3781.
- Zempel, H., Dennissen, F. J. A., Kumar, Y., Luedtke, J., Biernat, J., Mandelkow, E. M., & Mandelkow, E. (2017). Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture. *The Journal of Biological Chemistry* 292, 12192–12207.
- Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. M. (2013). Amyloid-beta oligomers induce synaptic damage via Tau-dependent microtubule severing by TLL6 and spastin. *The EMBO Journal* 32, 2920–2937.
- Zhao, X., Kotilinek, L. A., Smith, B., Hlynialuk, C., Zahs, K., Ramsden, M., ... Ashe, K. H. (2016). Caspase-2 cleavage of tau reversibly impairs memory. *Nature Medicine* 22, 1268–1276.
- Zhou, L., Martinez, S. J., Haber, M., Jones, E. V., Bouvier, D., Doucet, G., ... Murai, K. K. (2007). EphA4 signaling regulates phospholipase Cgamma1 activation, cofilin membrane association, and dendritic spine morphology. *The Journal of Neuroscience* 27, 5127–5138.
- Zhou, L., McInnes, J., Wierda, K., Holt, M., Herrmann, A. G., Jackson, R. J., ... Verstreken, P. (2017). Tau association with synaptic vesicles causes presynaptic dysfunction. *Nature Communications* 8, 15295.
- Zou, C., Crux, S., Marinesco, S., Montagna, E., Sgobio, C., Shi, Y., ... Herms, J. (2016). Amyloid precursor protein maintains constitutive and adaptive plasticity of dendritic spines in adult brain by regulating D-serine homeostasis. *The EMBO Journal* 35, 2213–2222.